Visit additional Tabor Communication Publications
January 11, 2012
On Tuesday, Life Technologies Corporation unveiled its newest DNA sequencer, which they claim can map a human genome in a day for a $1,000. That's just a fraction of the cost ($4,000 - $10,000) and time (two weeks or more) incurred by current platforms. Meanwhile rival Illumina Inc. has launched its latest DNA sequencing platform, which also purports to map a genome in a day. If the companies' claims hold up, such a performance increase will usher in a new era of genome sequencing.
But, as we've reported here before, interpreting those genes will limit how widely the technology can be applied. The analysis is the important step that turns the raw data into something useful, such as pointing the way to personalized drug treatment or assessing future risk of developing specific diseases.
Since such analysis requires sophisticated bioinformatics software and lots of computing muscle (that is, HPC-type hardware), this tends to be the most expensive and drawn-out step in the process. In general, interpreting the data can cost between 10 and 100 times as much as the sequencing. As was summed up rather well last year in a Genomics Law Report article:
[T]he goal is not inexpensive genomics, but personal genomics. What matters is not how much it costs to generate a genome sequence (i.e., raw data), but what you can do with that genome once you have it. Thus, genomics is only personal once both the data and the interpretation are individually tailored.
Because the analysis is costly, most analysts are skeptical that clinical genomics will be a reality anytime soon. The article quotes William Blair analyst Amanda Murphy, who believes that "the wide-scale incorporation of whole genome sequencing into the clinical realm is 10 or more years away."
Nevertheless, a glut of genomes will certainly spur demand for more "creative" solutions to the problem. The same Genomics Law Report piece points to a year-old Wired article that suggest DIY genomics will be an option for people who want to side-step the traditional health care system:
None of this is simple, but it will become easier with time. As the retail costs of sequencing drops, a substantial niche will develop for innovators providing affordable, intuitive, accurate interpretation tools (embryonic versions already exist: see, for instance, Promethease or Enlis Genomics). Open-source academic software built for large-scale sequencing projects will be adapted for use by non-specialists. The increasing availability of large-scale computing power (for instance, via Amazon EC2), coupled with this intuitive software, will make even compute-intensive analyses available to the educated, motivated lay-person.
Given the wariness traditional doctors have shown toward alternative healthcare, the medical establishment is not likely to embrace this approach. And as the article notes, such solutions are not suitable for everyone. But for those willing to educate themselves about the technology, "there's no reason why a DIY genome couldn't be every bit as useful (or indeed as useless, in many cases) as one obtained through the doctor-as-gatekeeper route."
Contributing commentator, Andrew Jones, offers a break in the news cycle with an assessment of what the national "size matters" contest means for the U.S. and other nations...
Today at the International Supercomputing Conference in Leipzing, Germany, Jack Dongarra presented on a proposed benchmark that could carry a bit more weight than its older Linpack companion. The high performance conjugate gradient (HPCG) concept takes into account new architectures for new applications, while shedding the floating point....
Not content to let the Tianhe-2 announcement ride alone, Intel rolled out a series of announcements around its Knights Corner and Xeon Phi products--all of which are aimed at adding some options and variety for a wider base of potential users across the HPC spectrum. Today at the International Supercomputing Conference, the company's Raj....
05/10/2013 | Cleversafe, Cray, DDN, NetApp, & Panasas | From Wall Street to Hollywood, drug discovery to homeland security, companies and organizations of all sizes and stripes are coming face to face with the challenges – and opportunities – afforded by Big Data. Before anyone can utilize these extraordinary data repositories, however, they must first harness and manage their data stores, and do so utilizing technologies that underscore affordability, security, and scalability.
04/15/2013 | Bull | “50% of HPC users say their largest jobs scale to 120 cores or less.” How about yours? Are your codes ready to take advantage of today’s and tomorrow’s ultra-parallel HPC systems? Download this White Paper by Analysts Intersect360 Research to see what Bull and Intel’s Center for Excellence in Parallel Programming can do for your codes.
Join HPCwire Editor Nicole Hemsoth and Dr. David Bader from Georgia Tech as they take center stage on opening night at Atlanta's first Big Data Kick Off Week, filmed in front of a live audience. Nicole and David look at the evolution of HPC, today's big data challenges, discuss real world solutions, and reveal their predictions. Exactly what does the future holds for HPC?
Join our webinar to learn how IT managers can migrate to a more resilient, flexible and scalable solution that grows with the data center. Mellanox VMS is future-proof, efficient and brings significant CAPEX and OPEX savings. The VMS is available today.